The Technical Analyst
NanoViricides Inc [NNVC]
Exchange: AMEX Industry: Biotechnology
NanoViricides Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.28% $1.890
America/New_York / 10 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 22.26 mill |
| EPS: | -0.800 |
| P/E: | -2.36 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 11.78 mill |
| Avg Daily Volume: | 0.0764 mill |
| RATING 2024-05-10 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.36 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.36 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.701 (-62.91%) $-1.189 |
| Date: 2024-05-12 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.799 - 1.981 ( +/- 4.81%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-08-08 | Diwan Anil | Sell | 94 471 | Common Stock, par value $0.001 per share |
| 2020-02-07 | Jawadakar Makarand | Buy | 0 | |
| 2019-06-02 | Day Mark D. | Buy | 0 | |
| 2018-05-21 | Boniuk Milton | Buy | 5 500 000 | Common Stock, par value $0.001 per share |
| 2017-02-21 | Boniuk Milton | Buy | 1 746 288 | Common Stock, par value $0.001 per share |
| INSIDER POWER |
|---|
| -100.00 |
| Last 95 transactions |
| Buy: 11 406 507 | Sell: 1 435 933 |
Forecast:
16:00 - $1.890
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.890
Forecast 2: 16:00 - $1.890
Forecast 3: 16:00 - $1.890
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.890 (3.28% ) |
| Volume | 0.193 mill |
| Avg. Vol. | 0.0764 mill |
| % of Avg. Vol | 252.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NNVC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NNVC
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Latest Press Releases
2024-05-10 06:30:00 - Press Release
Nanoviricides To Participate In The 2024 Ef Hutton Annual Global Conference On May 15 In New York City
Shelton, ct / accesswire / may 10, 2024 / nanoviricides, inc. (nyse american:nnvc) (the "company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that anil r. diwan, ph.d.
2024-05-08 06:30:00 - Press Release
A Novel Broad-spectrum Antiviral With Activity Against Smallpox/mpox
Nv-387 possesses strong orthopoxvirus activity relevant to both sexual and inhalation modes of transmission, says nanoviricides shelton, ct / accesswire / may 8, 2024 / nanoviricides, inc. (nyse american:nnvc) (the "company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of nv-387 includes activity against orthopoxvirus family (smallpox/mpox), with both inhalation and skin abrasion (sexual) modes of infection acquisition. ectromelia virus infection of mice is a model for smallpox infection in humans, and also serves as a surrogate for mpox infection in humans.
2024-05-06 06:30:00 - Press Release
A Novel Broad-spectrum Antiviral With Activity Against Influenza A
Nv-387 possesses strong anti-influenza-a virus activity, and may have activity against h5n1 bird flu virus, says nanoviricides shelton, ct / accesswire / may 6, 2024 / nanoviricides, inc. (nyse american:nnvc) (the "company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of nv-387 includes influenza a viruses, possibly including bird flu h5n1 virus as well. nanoviricides reports that in a lethal animal model of lung infection by influenza a /h3n2 virus, nv-387 was found to have substantially superior antiviral effects compared to three approved anti-influenza drugs.
2024-04-30 06:30:00 - Press Release
Nanoviricides Reports That The Phase I Nv-387 Clinical Trial Is Completed Successfully And Data Lock Is Expected Soon
Shelton, ct / accesswire / april 30, 2024 / nanoviricides, inc. (nyse amer:nnvc) (the "company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the phase i clinical trial of nv-387 is completed successfully and data lock is expected soon. the phase 1 clinical trial, protocol number km-nvcov2-001, which received approval from the regulatory agency in india for healthy as well as covid-19 participants, was closed and completed in april by the drug sponsor and our licensee, karveer meditech, pvt.
2024-02-15 06:30:00 - Press Release
Nanoviricides Has Filed Its Quarterly Report - Nv-387 Clinical Trial Healthy Subjects Part Successfully Completed, Covid Patient Treatment On The Horizon
Shelton, ct / accesswire / february 15, 2024 / nanoviricides, inc. (nyse american:nnvc) (the "company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its quarterly report on form 10-q for the fiscal second quarter ending december 31, 2023 with the securities and exchange commission (sec) on wednesday, february 14, 2024. the report can be accessed at the sec website at https://www.sec.gov/archives/edgar/data/1379006/000141057824000048/nnvc-20231231x10q.htm.
Latest News
2024-05-10 09:01:57 - Proactive Investors
NanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global Conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held in New York on May 15, 2024, which brings together institutional investors, high-net-worth individuals, corporate clients and the press with public and private company executives. At the conference, CEO Dr Anil Diwan will share with investors the company's progress over the last year.
2024-05-08 09:13:03 - Proactive Investors
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox
NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the orthopoxvirus family of viruses, which includes Smallpox and Mpox, in both inhalation and sexual modes of transmission. In a lethal animal model of lung infection by the Ectromelia virus, a model for Smallpox and Mpox infection in humans, NV-387 led to an increase in the mice's lifespan comparable to oral treatment with approved Smallpox drug tecovirimat.
2024-05-06 09:18:52 - Proactive Investors
NanoViricides drug asset shows ‘superior antiviral effects' against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses. The company said that in a lethal animal model of lung infection by Influenza A/H3N2 virus, NV-387 demonstrated “substantially superior antiviral effects” compared to three approved anti-influenza drugs, Oseltamivir, Peramivir, and Baloxivir.
2024-04-30 09:11:29 - Proactive Investors
NanoViricides completes Phase 1 trial of lead asset NV-387
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader in broad-spectrum antiviral nanomedicines, is developing NV-387 as a therapeutic for respiratory viral infections.
2024-02-15 10:18:24 - Proactive Investors
NanoViricides boosts liquidity measures and manufacturing capacity to support clinical trials
NanoViricides (NYSE-A:NNVC) said it is making good progress in its antiviral drug development program, with strong safety data for its lead candidate NV-CoV-2 and enhanced liquidity measures positioning the company for future clinical trials and market expansion. Financially, NanoViricides (NYSE-A:NNVC) reported a cash and cash equivalent current assets balance of approximately $5.31 million as of December 31, 2023, with additional agreements providing approximately $2.5 million available cash, totaling around $7.8 million cash available to the company.
2024-02-02 10:16:10 - Proactive Investors
Pioneering nanomedicine: NanoViricides making big strides fighting viral infections
NanoViricides (NYSE-A:NNVC) has a platform that shows a versatile and effective approach to antiviral therapy, with potential applications that target a broad spectrum of viral diseases. The clinical stage company, pioneering nanomedicine for antiviral therapy, is making significant strides in its fight against viral infections.
2024-02-01 08:39:51 - Proactive Investors
NanoViricides highlights lead asset NV-387's potential to revolutionize the treatment of antiviral infections
NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the active ingredient NV-387 shows that they have implications beyond COVID. NV-387 is an ultra-broad-spectrum antiviral nanomedicine that was designed by copying a common host-side chemical signature used by viruses to infect and cause disease in humans and animals, the company said.
2024-01-30 14:56:50 - Proactive Investors
NanoViricides' potential to address dozens of diseases highlighted by analysts following trial success
NanoViricides (NYSE-A:NNVC) has earned a ‘Buy' rating and a $6.50 price target from EFHutton analysts after the company released positive safety results from its Phase 1a/1b clinical study involving its lead asset NV-387. Shares of NanoViricides (NYSE-A:NNVC) traded hands at about US$1.12 on Tuesday afternoon.
2024-01-04 06:30:00 - Accesswire
NanoViricides to Present at the Biotech Showcase in San Fransisco
SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 9, 2024 Time, Track & Room 3:30pm PT, Yosemite C (Ballroom Level) Location Hilton San Fransisco - Union Square This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event.
2023-11-28 09:19:53 - Proactive Investors
NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug
NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, with no adverse events reported in any of the three dose levels from the two formulations used in the study, namely NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.